Antrodia camphorata, a medicinal fungus native to Taiwan, has been traditionally used for various ailments, but in recent years, scientific interest has focused on its potential metabolic benefits. Preclinical studies (primarily in vitro and in animal models) have demonstrated that extracts of A. camphorata can exert antihyperglycemic, antihyperlipidemic, and anti-inflammatory effects. For example, several studies in high-fat diet-induced obese mice showed that supplementation with A. camphorata extracts improved insulin sensitivity, lowered fasting blood glucose, reduced serum triglycerides and cholesterol, and attenuated liver steatosis. Proposed mechanisms include modulation of AMPK signaling, enhancement of antioxidant enzyme activity, and inhibition of inflammatory cytokines.

Despite promising preclinical data, clinical evidence in humans is limited. A few small-scale human trials and pilot studies have investigated the effects of A. camphorata supplementation on metabolic parameters, such as blood glucose and lipid profiles, in patients with type 2 diabetes or metabolic syndrome. Results suggest some beneficial trends, but studies are often underpowered, lack rigorous controls, or are of short duration. No large, well-designed randomized controlled trials have definitively established efficacy or safety in this population.

In summary, while there is emerging scientific interest and preliminary evidence supporting the use of Antrodia camphorata for metabolic syndrome, robust clinical evidence is currently lacking, justifying a moderate evidence rating.